

Samuel C Blackman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/12101067/publications.pdf>

Version: 2024-02-01

16
papers

1,364
citations

687363

13
h-index

996975

15
g-index

16
all docs

16
docs citations

16
times ranked

2055
citing authors

#	ARTICLE	IF	CITATIONS
1	Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. <i>Lancet, The</i> , 2012, 379, 1893-1901.	13.7	856
2	Postcesarean Analgesia with Both Epidural Morphine and Intravenous Patient-Controlled Analgesia. <i>Anesthesia and Analgesia</i> , 1997, 85, 600-606.	2.2	75
3	Dose Selection, Pharmacokinetics, and Pharmacodynamics of BRAF Inhibitor Dabrafenib (GSK2118436). <i>Clinical Cancer Research</i> , 2014, 20, 4449-4458.	7.0	56
4	The Identification and Characterization of Oligodendrocyte Thromboxane A2 Receptors. <i>Journal of Biological Chemistry</i> , 1998, 273, 475-483.	3.4	46
5	Opioid Antagonist Adjuncts to Epidural Morphine for Postcesarean Analgesia. <i>Anesthesia and Analgesia</i> , 1993, 77, 925-932.	2.2	43
6	Metabolism and Disposition of Oral Dabrafenib in Cancer Patients: Proposed Participation of Aryl Nitrogen in Carbon-Carbon Bond Cleavage via Decarboxylation following Enzymatic Oxidation. <i>Drug Metabolism and Disposition</i> , 2013, 41, 2215-2224.	3.3	41
7	Effects of particle size, food, and capsule shell composition on the oral bioavailability of dabrafenib, a BRAF inhibitor, in patients with BRAF mutation-positive tumors. <i>Journal of Pharmaceutical Sciences</i> , 2013, 102, 3100-3109.	3.3	39
8	Postcesarean Analgesia with Both Epidural Morphine and Intravenous Patient-Controlled Analgesia. <i>Anesthesia and Analgesia</i> , 1997, 85, 600-606.	2.2	38
9	Assessment of the drug interaction potential and single- and repeat-dose pharmacokinetics of the BRAF inhibitor dabrafenib. <i>Journal of Clinical Pharmacology</i> , 2015, 55, 392-400.	2.0	37
10	Forehead swelling caused by Pott's puffy tumor in a 9-year-old boy with sinusitis. <i>Pediatrics International</i> , 2005, 47, 704-707.	0.5	36
11	Concomitant Oral and Intravenous Pharmacokinetics of Dabrafenib, a BRAF Inhibitor, in Patients with BRAF V600 Mutation-Positive Solid Tumors. <i>Journal of Clinical Pharmacology</i> , 2013, 53, 955-961.	2.0	35
12	Emergence and Compartmentalization of Fatal Multi-Drug-Resistant Cytomegalovirus Infection in a Patient With Autosomal-Recessive Severe Combined Immune Deficiency. <i>Journal of Pediatric Hematology/Oncology</i> , 2004, 26, 601-605.	0.6	23
13	Identification and functional characterization of thromboxane A2 receptors in Schwann cells. <i>Journal of Neurochemistry</i> , 2001, 78, 446-456.	3.9	22
14	Prenatal Diagnosis and Subsequent Treatment of an Intermediate-Risk Paraspinal Neuroblastoma: Case Report and Review of the Literature. <i>Fetal Diagnosis and Therapy</i> , 2008, 24, 119-125.	1.4	13
15	Assessment of Cellular Localization of the Thromboxane A ₂ Receptor by Immunocytochemistry. <i>Journal of Cellular Biochemistry</i> , 1999, 120, 145-171.		3
16	Abstract 3773: Absolute bioavailability of BRAF inhibitor GSK2118436: Use of a microtracer study in patients with cancer. <i>Cancer Research</i> , 2012, 72, 3773-3773.	0.9	1